{"id":55182,"date":"2023-03-24T19:04:49","date_gmt":"2023-03-24T18:04:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/"},"modified":"2023-03-24T19:04:49","modified_gmt":"2023-03-24T18:04:49","slug":"resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/","title":{"rendered":"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity"},"content":{"rendered":"
\n

\nFinancing focused on domestic biomanufacturing capacity and capabilities for biologics, vaccines, and nucleic acids<\/i>\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–#biomanufacturing<\/a>–National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC).\n<\/p>\n

<\/a><\/p>\n

\nThe loan financing will support Resilience\u2019s mission to establish significant domestic, end-to-end biomanufacturing capacity and capabilities for biologics (antibodies, proteins, multi-specifics), vaccines, and nucleic acids (including mRNA). This expanded capacity, together with existing technology and capabilities across Resilience\u2019s biomanufacturing network, will help secure the nation\u2019s supply chain for vaccines and critical medicines, bolster pandemic preparedness and response, and help address a critical advanced manufacturing infrastructure shortage revealed by the COVID-19 pandemic. Part of the financing will support the implementation of innovative manufacturing platforms and technologies that aim to reduce cost, strengthen the domestic supply chain, and increase the speed of vaccine supply.\n<\/p>\n

\nThe long-term financing also strengthens Resilience\u2019s ability to deliver the highest quality products to patients and to the 50-plus commercial customers that utilize its nearly two million square feet of end-to-end drug development capacity and solutions that span process and analytical development and GMP biomanufacturing across multiple therapeutic modalities. With this support, Resilience will be able to manufacture a billion doses of vaccines within its manufacturing network in the United States and will continue to partner with biotech and biopharma innovators across the drug development life cycle.\n<\/p>\n

\n“The lack of growth and innovation in domestic biomanufacturing was one critical vulnerability that impacted preparedness during the COVID-19 pandemic. This partnership is one of the many ways we are developing a more vibrant biopharmaceutical manufacturing ecosystem to keep pace with new scientific advancements and produce novel, safe, life-saving discoveries quickly and at scale to benefit the nation,\u201d said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. \u201cResilience is honored to partner with the DFC, DoD, and the U.S. government to ensure this country can maintain its innovative, competitive edge in biotechnology and biomanufacturing, while generating significant benefits to the health, security, and quality of American lives and those around the world.\u201d\n<\/p>\n

\nAbout Resilience<\/b>\n<\/p>\n

\nResilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell therapy, and gene therapy modalities). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients\u2019 lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https:\/\/resilience.com\/<\/a> and follow us on social media: @IncResilience<\/a> on Twitter and Resilience<\/a> on LinkedIn.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMichele Roberts<\/b>
Head of Communications
\n
Michele.roberts@Resilience.com<\/a>
M: +16092848213\n<\/p>\n

\nTatjana Heller<\/b>
Head of Investor Relations and Analytics
\n
Tatjana.heller@resilience.com<\/a>
+17745734579\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Financing focused on domestic biomanufacturing capacity and capabilities for biologics, vaccines, and nucleic acids SAN DIEGO–(BUSINESS WIRE)–#biomanufacturing–National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55182","6":"format-standard","7":"category-industry"},"yoast_head":"\nResilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Financing focused on domestic biomanufacturing capacity and capabilities for biologics, vaccines, and nucleic acids SAN DIEGO–(BUSINESS WIRE)–#biomanufacturing–National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-24T18:04:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230324005083\/en\/1746525\/21\/02_PNG_Res_Logo_Black.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity\",\"datePublished\":\"2023-03-24T18:04:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/\"},\"wordCount\":527,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230324005083\\\/en\\\/1746525\\\/21\\\/02_PNG_Res_Logo_Black.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/\",\"name\":\"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230324005083\\\/en\\\/1746525\\\/21\\\/02_PNG_Res_Logo_Black.jpg\",\"datePublished\":\"2023-03-24T18:04:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230324005083\\\/en\\\/1746525\\\/21\\\/02_PNG_Res_Logo_Black.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230324005083\\\/en\\\/1746525\\\/21\\\/02_PNG_Res_Logo_Black.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/","og_locale":"en_US","og_type":"article","og_title":"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity - Pharma Trend","og_description":"Financing focused on domestic biomanufacturing capacity and capabilities for biologics, vaccines, and nucleic acids SAN DIEGO–(BUSINESS WIRE)–#biomanufacturing–National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-24T18:04:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230324005083\/en\/1746525\/21\/02_PNG_Res_Logo_Black.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity","datePublished":"2023-03-24T18:04:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/"},"wordCount":527,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230324005083\/en\/1746525\/21\/02_PNG_Res_Logo_Black.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/","url":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/","name":"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230324005083\/en\/1746525\/21\/02_PNG_Res_Logo_Black.jpg","datePublished":"2023-03-24T18:04:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230324005083\/en\/1746525\/21\/02_PNG_Res_Logo_Black.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230324005083\/en\/1746525\/21\/02_PNG_Res_Logo_Black.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/resilience-approved-for-410m-financing-from-the-department-of-defense-in-partnership-with-the-development-finance-corporation-to-establish-resilient-biomanufacturing-capacity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55182"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55182\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}